GSE41994
Breat cancer dataset (Cancer Res. 2013, 107 patients)
SUBTYPE | SUBTYPE2 | SUBTYPE3 | age at diagnosis | age at start therapy | disease progression (event) | disease relapse (event) | disease-free interval (months) | er status | gender | grade | her2 status | location | menopausal status at start therapy | pik3ca status | pr status | time-to-progession (months) | tissue | treatment type | tumor type | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSM1029704 | ER+ | ER+ | ER+ | 82 | 84 | 0 | 1 | 31 | positive | female | 2 | NaN | breast | post | wildtype | negative | 8 | breast | anastrozole | invasive ductal carcinoma |
GSM1029705 | ER+ | ER+ | ER+ | 69 | 71 | 0 | 1 | 31 | positive | female | 2 | negative | breast | post | E545K | positive | 38 | breast | letrozole | invasive ductal carcinoma |
GSM1029706 | NaN | NaN | NaN | 72 | 76 | 1 | 1 | 43 | negative | female | 3 | NaN | breast | post | wildtype | negative | 3 | breast | letrozole | invasive ductal carcinoma |
GSM1029707 | ER+ | ER+ | ER+ | 44 | 48 | 0 | 1 | 50 | positive | female | 2 | negative | breast | post | E545K | positive | 16 | breast | anastrozole | invasive ductal carcinoma |
GSM1029708 | ER+ | ER+ | ER+ | 51 | 54 | 1 | 1 | 30 | positive | female | 3 | negative | breast | pre | wildtype | positive | 3 | breast | letrozole | invasive ductal carcinoma |
GSM1029709 | ER+ | ER+ | ER+ | 63 | 66 | 1 | 1 | 0 | positive | female | 2 | NaN | breast | post | wildtype | NaN | 2 | breast | anastrozole | invasive ductal carcinoma |
GSM1029710 | ER+ | ER+ | ER+ | 70 | 78 | 1 | 1 | 113 | positive | female | NaN | negative | breast | post | wildtype | positive | 18 | breast | anastrozole | invasive ductal carcinoma |
GSM1029711 | ER+ | ER+ | ER+ | 51 | 59 | 1 | 1 | 112 | positive | female | 3 | negative | breast | post | H1047R | positive | 53 | breast | anastrozole | invasive ductal carcinoma |
GSM1029712 | ER+ | ER+ | ER+ | 76 | 81 | 1 | 1 | 43 | positive | female | NaN | NaN | breast | post | wildtype | negative | 10 | breast | anastrozole | invasive ductal carcinoma |
GSM1029713 | NaN | NaN | NaN | 51 | 58 | 1 | 1 | 87 | NaN | female | NaN | NaN | breast | post | H1047R | negative | 5 | breast | anastrozole | invasive ductal carcinoma |
GSM1029714 | ER+ | ER+ | ER+ | 68 | 80 | 0 | 1 | 141 | positive | female | 3 | NaN | breast | post | wildtype | positive | 25 | breast | letrozole | invasive ductal carcinoma |
GSM1029715 | ER+ | ER+ | ER+ | 56 | 64 | 1 | 1 | 111 | positive | female | 2 | NaN | breast | post | H1047R | positive | 53 | breast | letrozole | invasive ductal carcinoma |
GSM1029716 | ER+ | ER+ | ER+ | 64 | 73 | 1 | 1 | 120 | positive | female | 2 | negative | breast | post | wildtype | positive | 26 | breast | letrozole | invasive ductal carcinoma |
GSM1029717 | ER+ | ER+ | ER+ | 76 | 79 | 1 | 1 | 40 | positive | female | 1 | NaN | breast | post | wildtype | positive | 30 | breast | anastrozole | invasive ductal carcinoma |
GSM1029718 | ER+ | ER+ | ER+ | 83 | 85 | 0 | 1 | 37 | positive | female | 1 | negative | breast | post | H1047R | positive | 2 | breast | anastrozole | invasive ductal carcinoma |
GSM1029719 | ER+ | ER+ | ER+ | 71 | 76 | 1 | 1 | 67 | positive | female | 2 | negative | breast | post | wildtype | positive | 7 | breast | anastrozole | invasive ductal carcinoma |
GSM1029720 | ER+ | ER+ | ER+ | 58 | 59 | 1 | 1 | 23 | positive | female | NaN | NaN | breast | post | wildtype | positive | 8 | breast | anastrozole | invasive ductal carcinoma |
GSM1029721 | ER+ | ER+ | ER+ | 60 | 61 | 1 | 1 | 18 | positive | female | 3 | negative | breast | post | wildtype | positive | 10 | breast | anastrozole | invasive ductal carcinoma |
GSM1029722 | ER+ | ER+ | ER+ | 67 | 72 | 0 | 1 | 70 | positive | female | 2 | negative | breast | post | wildtype | positive | 2 | breast | letrozole | invasive ductal carcinoma |
GSM1029723 | ER+ | ER+ | ER+ | NaN | 82 | 0 | 1 | 59 | positive | female | 2 | negative | breast | post | wildtype | positive | 1 | breast | letrozole | invasive ductal carcinoma |
GSM1029724 | ER+ | ER+ | ER+ | 67 | 70 | 1 | 1 | 46 | positive | female | 2 | negative | breast | post | wildtype | positive | 4 | breast | anastrozole | invasive ductal carcinoma |
GSM1029725 | ER+ | ER+ | ER+ | 49 | 51 | 1 | 1 | 29 | positive | female | 3 | negative | breast | post | H1047R | positive | 6 | breast | anastrozole | invasive ductal carcinoma |
GSM1029726 | HER2+ | ER+ | ER+/HER2+ | 63 | 66 | 1 | 1 | 45 | positive | female | 3 | positive | breast | post | wildtype | negative | 21 | breast | anastrozole | invasive ductal carcinoma |
GSM1029727 | ER+ | ER+ | ER+ | 65 | 67 | 1 | 1 | 37 | positive | female | 3 | negative | breast | post | wildtype | negative | 12 | breast | anastrozole | invasive ductal carcinoma |
GSM1029728 | ER+ | ER+ | ER+ | 78 | 83 | 1 | 1 | 66 | positive | female | NaN | negative | breast | post | H1047R | positive | 13 | breast | anastrozole | invasive ductal carcinoma |
GSM1029729 | HER2+ | ER+ | ER+/HER2+ | 45 | 51 | 1 | 1 | 82 | positive | female | 3 | positive | breast | post | H1047R | positive | 11 | breast | letrozole | invasive ductal carcinoma |
GSM1029730 | ER+ | ER+ | ER+ | 51 | 56 | 1 | 1 | 63 | positive | female | 1 | negative | breast | post | wildtype | positive | 10 | breast | anastrozole | invasive ductal carcinoma |
GSM1029731 | ER+ | ER+ | ER+ | 58 | 59 | 1 | 1 | 24 | positive | female | 3 | negative | breast | post | wildtype | negative | 10 | breast | exemestane | invasive ductal carcinoma |
GSM1029732 | ER+ | ER+ | ER+ | 52 | 54 | 1 | 1 | 24 | positive | female | 2 | negative | breast | post | wildtype | negative | 8 | breast | anastrozole | invasive ductal carcinoma |
GSM1029733 | ER+ | ER+ | ER+ | 62 | 64 | 1 | 1 | 36 | positive | female | 3 | negative | breast | post | wildtype | positive | 13 | breast | letrozole | invasive ductal carcinoma |
GSM1029734 | ER+ | ER+ | ER+ | 55 | 61 | 1 | 1 | 78 | positive | female | 3 | negative | breast | post | wildtype | negative | 12 | breast | anastrozole | invasive ductal carcinoma |
GSM1029735 | HER2+ | ER+ | ER+/HER2+ | 51 | 54 | 0 | 1 | 39 | positive | female | 2 | positive | breast | post | H1047R | positive | 56 | breast | letrozole | invasive ductal carcinoma |
GSM1029736 | ER+ | ER+ | ER+ | 56 | 58 | 1 | 1 | 40 | positive | female | 2 | negative | breast | post | wildtype | NaN | 14 | breast | letrozole | invasive ductal carcinoma |
GSM1029737 | ER+ | ER+ | ER+ | 84 | 86 | 1 | 1 | 33 | positive | female | 2 | negative | breast | post | H1047R | positive | 4 | breast | letrozole | invasive ductal carcinoma |
GSM1029738 | HER2+ | ER+ | ER+/HER2+ | 78 | 80 | 1 | 1 | 35 | positive | female | 3 | positive | breast | post | H1047R | positive | 8 | breast | exemestane | invasive ductal carcinoma |
GSM1029739 | ER+ | ER+ | ER+ | 69 | 71 | 0 | 1 | 23 | positive | female | 2 | negative | breast | post | H1047R | positive | 25 | breast | letrozole | invasive ductal carcinoma |
GSM1029740 | ER+ | ER+ | ER+ | 74 | 73 | 1 | 1 | 0 | positive | female | 2 | negative | breast | post | wildtype | positive | 16 | breast | anastrozole | invasive ductal carcinoma |
GSM1029741 | ER+ | ER+ | ER+ | 62 | 64 | 1 | 1 | 25 | positive | female | 3 | negative | breast | post | wildtype | negative | 3 | breast | letrozole | invasive ductal carcinoma |
GSM1029742 | ER+ | ER+ | ER+ | 67 | 69 | 0 | 1 | 31 | positive | female | 1 | negative | breast | post | wildtype | positive | 18 | breast | anastrozole | invasive ductal carcinoma |
GSM1029743 | ER+ | ER+ | ER+ | 50 | 49 | 1 | 1 | 0 | positive | female | NaN | negative | breast | pre | wildtype | negative | 12 | breast | letrozole | invasive ductal carcinoma |
GSM1029744 | ER+ | ER+ | ER+ | 59 | 58 | 1 | 1 | 0 | positive | female | 1 | negative | breast | post | wildtype | positive | 26 | breast | letrozole | invasive ductal carcinoma |
GSM1029745 | ER+ | ER+ | ER+ | 55 | 54 | 0 | 1 | 0 | positive | female | NaN | negative | breast | post | wildtype | negative | 11 | breast | letrozole | invasive ductal carcinoma |
GSM1029746 | ER+ | ER+ | ER+ | 75 | 76 | 1 | 1 | 24 | positive | female | 2 | negative | breast | post | wildtype | positive | 26 | breast | letrozole | invasive ductal carcinoma |
GSM1029747 | ER+ | ER+ | ER+ | 51 | 54 | 1 | 1 | 30 | positive | female | 3 | NaN | breast | NaN | wildtype | positive | 3 | breast | letrozole | invasive ductal carcinoma |
GSM1029748 | ER+ | ER+ | ER+ | 63 | 67 | 1 | 1 | 47 | positive | female | 3 | NaN | breast | post | H1047R | positive | 28 | breast | anastrozole | invasive ductal carcinoma |
GSM1029749 | NaN | NaN | NaN | 82 | 85 | 1 | 1 | 35 | negative | female | 1 | NaN | breast | post | wildtype | negative | 14 | breast | anastrozole | invasive ductal carcinoma |
GSM1029750 | ER+ | ER+ | ER+ | 52 | 57 | 1 | 1 | 29 | positive | female | 3 | negative | breast | post | wildtype | positive | 6 | breast | anastrozole | invasive ductal carcinoma |
GSM1029751 | ER+ | ER+ | ER+ | 61 | 76 | 0 | 1 | 186 | positive | female | NaN | NaN | breast | post | wildtype | positive | 31 | breast | anastrozole | invasive ductal carcinoma |
GSM1029752 | ER+ | ER+ | ER+ | 48 | 58 | 1 | 1 | 102 | positive | female | 1 | NaN | breast | post | H1047R | positive | 52 | breast | anastrozole | invasive ductal carcinoma |
GSM1029753 | NaN | NaN | NaN | 69 | 72 | 1 | 1 | 41 | negative | female | 2 | NaN | breast | post | wildtype | negative | 11 | breast | anastrozole | invasive ductal carcinoma |
GSM1029754 | NaN | NaN | NaN | 53 | 57 | 1 | NaN | NaN | NaN | female | NaN | NaN | breast | post | wildtype | NaN | 6 | breast | anastrozole | invasive ductal carcinoma |
GSM1029755 | ER+ | ER+ | ER+ | 59 | 62 | 0 | 1 | 41 | positive | female | 2 | NaN | breast | post | wildtype | negative | 11 | breast | letrozole | invasive ductal carcinoma |
GSM1029756 | ER+ | ER+ | ER+ | 78 | 80 | 1 | 1 | 24 | positive | female | 3 | NaN | breast | post | H1047R | positive | 17 | breast | anastrozole | invasive ductal carcinoma |
GSM1029757 | ER+ | ER+ | ER+ | 58 | 68 | 1 | 1 | 123 | positive | female | NaN | NaN | breast | post | wildtype | positive | 7 | breast | letrozole | invasive ductal carcinoma |
GSM1029758 | ER+ | ER+ | ER+ | 73 | 76 | 1 | 1 | 24 | positive | female | 2 | negative | breast | post | E545K | positive | 30 | breast | exemestane | invasive ductal carcinoma |
GSM1029759 | ER+ | ER+ | ER+ | 69 | 70 | 1 | 1 | 11 | positive | female | 2 | negative | breast | post | wildtype | positive | 2 | breast | exemestane | invasive ductal carcinoma |
GSM1029760 | ER+ | ER+ | ER+ | 56 | 56 | 1 | 1 | 0 | positive | female | 2 | negative | breast | post | H1047R | negative | 18 | breast | anastrozole | invasive ductal carcinoma |
GSM1029761 | ER+ | ER+ | ER+ | 50 | 51 | 1 | 1 | 18 | positive | female | 3 | negative | breast | post | wildtype | positive | 14 | breast | exemestane | invasive ductal carcinoma |
GSM1029762 | ER+ | ER+ | ER+ | 34 | 35 | 0 | 1 | 14 | positive | female | 2 | negative | breast | post | wildtype | positive | NaN | breast | letrozole | invasive ductal carcinoma |
GSM1029763 | ER+ | ER+ | ER+ | 56 | 64 | NaN | 1 | 7 | positive | female | 3 | negative | breast | post | wildtype | negative | NaN | breast | exemestane | invasive ductal carcinoma |
GSM1029764 | HER2+ | ER+ | ER+/HER2+ | 37 | NaN | NaN | NaN | NaN | positive | female | NaN | positive | breast | NaN | wildtype | positive | NaN | breast | NaN | invasive ductal carcinoma |
GSM1029765 | ER+ | ER+ | ER+ | 80 | 88 | NaN | 1 | 0 | positive | female | 1 | NaN | breast | post | NaN | negative | NaN | breast | exemestane | invasive ductal carcinoma |
GSM1029766 | ER+ | ER+ | ER+ | 76 | 79 | 0 | 1 | 36 | positive | female | 2 | negative | breast | post | wildtype | positive | 30 | breast | exemestane | invasive ductal carcinoma |
GSM1029767 | ER+ | ER+ | ER+ | 67 | 67 | 1 | 1 | 28 | positive | female | 1 | negative | breast | post | wildtype | positive | 11 | breast | exemestane | invasive ductal carcinoma |
GSM1029768 | HER2+ | ER+ | ER+/HER2+ | 55 | 60 | 1 | 1 | 46 | positive | female | 3 | positive | breast | post | wildtype | negative | NaN | breast | anastrozole | invasive ductal carcinoma |
GSM1029769 | ER+ | ER+ | ER+ | 60 | 62 | 1 | 1 | 16 | positive | female | 3 | NaN | breast | post | wildtype | negative | 12 | breast | anastrozole | invasive ductal carcinoma |
GSM1029770 | ER+ | ER+ | ER+ | 71 | 76 | 1 | 1 | 53 | positive | female | 2 | NaN | breast | post | wildtype | negative | 39 | breast | anastrozole | invasive ductal carcinoma |
GSM1029771 | NaN | NaN | NaN | 35 | 37 | 1 | 1 | 25 | negative | female | 3 | NaN | breast | post | wildtype | positive | 5 | breast | exemestane | invasive ductal carcinoma |
GSM1029772 | ER+ | ER+ | ER+ | 85 | 88 | NaN | 1 | 40 | positive | female | 3 | negative | breast | post | wildtype | positive | NaN | breast | tamoxifen | invasive ductal carcinoma |
GSM1029773 | ER+ | ER+ | ER+ | 41 | 43 | 0 | 1 | 27 | positive | female | 2 | negative | breast | NaN | wildtype | positive | NaN | breast | letrozole | invasive ductal carcinoma |
GSM1029774 | ER+ | ER+ | ER+ | 77 | 79 | 1 | 1 | 14 | positive | female | 2 | NaN | breast | post | wildtype | negative | 13 | breast | anastrozole | invasive ductal carcinoma |
GSM1029775 | ER+ | ER+ | ER+ | 52 | 56 | 1 | 1 | 49 | positive | female | 2 | negative | breast | post | E542K | positive | 31 | breast | letrozole | invasive ductal carcinoma |
GSM1029776 | NaN | NaN | NaN | 70 | 76 | 1 | 1 | 72 | negative | female | 2 | NaN | breast | post | wildtype | NaN | 3 | breast | anastrozole | invasive ductal carcinoma |
GSM1029777 | ER+ | ER+ | ER+ | 41 | 44 | 1 | 1 | 34 | positive | female | 3 | negative | breast | na | E542K | positive | 8 | breast | anastrozole | invasive ductal carcinoma |
GSM1029778 | HER2+ | ER+ | ER+/HER2+ | 32 | 44 | 0 | 1 | 131 | positive | female | 1 | positive | breast | pre | E542K | positive | 47 | breast | letrozole | invasive ductal carcinoma |
GSM1029779 | ER+ | ER+ | ER+ | 36 | 54 | 1 | 1 | 219 | positive | female | 3 | negative | breast | pre | H1047R | positive | 27 | breast | anastrozole | invasive ductal carcinoma |
GSM1029780 | ER+ | ER+ | ER+ | 44 | 48 | 1 | 1 | 48 | positive | female | 2 | negative | breast | post | H1047R | positive | 6 | breast | tamoxifen | invasive ductal carcinoma |
GSM1029781 | ER+ | ER+ | ER+ | 44 | 47 | 1 | 1 | 33 | positive | female | 2 | negative | breast | post | wildtype | positive | 10 | breast | anastrozole | invasive ductal carcinoma |
GSM1029782 | ER+ | ER+ | ER+ | 68 | 72 | 1 | 1 | 44 | positive | female | 2 | negative | breast | post | wildtype | positive | 10 | breast | anastrozole | invasive ductal carcinoma |
GSM1029783 | ER+ | ER+ | ER+ | 44 | 47 | 1 | 1 | 37 | positive | female | 1 | negative | breast | pre | wildtype | negative | 19 | breast | exemestane | invasive ductal carcinoma |
GSM1029784 | HER2+ | ER+ | ER+/HER2+ | 76 | 78 | 1 | 1 | 15 | positive | female | 2 | positive | breast | post | wildtype | negative | 7 | breast | exemestane | invasive ductal carcinoma |
GSM1029785 | ER+ | ER+ | ER+ | 75 | 79 | 1 | 1 | 45 | positive | female | 2 | negative | breast | post | wildtype | positive | 7 | breast | exemestane | invasive ductal carcinoma |
GSM1029786 | ER+ | ER+ | ER+ | 55 | 56 | 1 | 1 | 10 | positive | female | 3 | NaN | breast | post | wildtype | positive | 4 | breast | anastrozole | invasive ductal carcinoma |
GSM1029787 | ER+ | ER+ | ER+ | 60 | 62 | 1 | 1 | 23 | positive | female | 3 | NaN | breast | post | wildtype | positive | 3 | breast | anastrozole | invasive ductal carcinoma |
GSM1029788 | ER+ | ER+ | ER+ | 63 | 77 | 0 | 1 | 110 | positive | female | NaN | NaN | breast | post | wildtype | positive | 25 | breast | letrozole | invasive ductal carcinoma |
GSM1029789 | HER2+ | HER2+ | ER-/HER2+ | 43 | 49 | 1 | 1 | 76 | negative | female | NaN | positive | breast | post | H1047R | negative | 5 | breast | anastrozole | invasive ductal carcinoma |
GSM1029790 | ER+ | ER+ | ER+ | 38 | 47 | 1 | 1 | 100 | positive | female | 2 | NaN | breast | post | H1047R | positive | 6 | breast | anastrozole | invasive ductal carcinoma |
GSM1029791 | ER+ | ER+ | ER+ | 69 | 71 | 1 | 1 | 24 | positive | female | 2 | negative | breast | post | wildtype | positive | 29 | breast | anastrozole | invasive ductal carcinoma |
GSM1029792 | ER+ | ER+ | ER+ | 76 | NaN | NaN | NaN | NaN | positive | female | 2 | negative | breast | post | wildtype | positive | NaN | breast | NaN | invasive ductal carcinoma |
GSM1029793 | ER+ | ER+ | ER+ | 80 | 84 | 1 | 1 | 39 | positive | female | 2 | negative | breast | post | E545K | positive | 2 | breast | exemestane | invasive ductal carcinoma |
GSM1029794 | ER+ | ER+ | ER+ | 49 | 55 | 1 | 1 | 76 | positive | female | 2 | negative | breast | post | E545K | positive | 8 | breast | exemestane | invasive ductal carcinoma |
GSM1029795 | ER+ | ER+ | ER+ | 65 | 68 | 1 | 1 | 42 | positive | female | 3 | negative | breast | post | wildtype | negative | 6 | breast | anastrozole | invasive ductal carcinoma |
GSM1029796 | ER+ | ER+ | ER+ | 33 | 35 | 1 | 1 | 27 | positive | female | 2 | negative | breast | pre | wildtype | negative | 5 | breast | anastrozole | invasive ductal carcinoma |
GSM1029797 | ER+ | ER+ | ER+ | 50 | 54 | 1 | 1 | 49 | positive | female | 3 | NaN | breast | post | H1047R | positive | 11 | breast | exemestane | invasive ductal carcinoma |
GSM1029798 | ER+ | ER+ | ER+ | 58 | 64 | 1 | 1 | 66 | positive | female | NaN | NaN | breast | post | wildtype | negative | 17 | breast | anastrozole | invasive ductal carcinoma |
GSM1029799 | ER+ | ER+ | ER+ | 48 | 57 | 0 | NaN | NaN | positive | female | 3 | NaN | breast | post | wildtype | negative | 6 | breast | anastrozole | invasive ductal carcinoma |
GSM1029800 | ER+ | ER+ | ER+ | 32 | 35 | 1 | 1 | 9 | positive | female | 3 | negative | breast | pre | wildtype | positive | 14 | breast | letrozole | invasive ductal carcinoma |
GSM1029801 | ER+ | ER+ | ER+ | 74 | 80 | 1 | 1 | 83 | positive | female | 2 | NaN | breast | post | wildtype | positive | 24 | breast | letrozole | invasive ductal carcinoma |
GSM1029802 | ER+ | ER+ | ER+ | 81 | 81 | 1 | 1 | 11 | positive | female | 3 | negative | breast | post | wildtype | positive | 4 | breast | letrozole | invasive ductal carcinoma |
GSM1029803 | ER+ | ER+ | ER+ | 79 | 81 | 1 | 1 | 1 | positive | female | 2 | negative | breast | post | wildtype | negative | 5 | breast | exemestane | invasive ductal carcinoma |
GSM1029804 | ER+ | ER+ | ER+ | 75 | 75 | NaN | 1 | 0 | positive | female | 2 | negative | breast | post | wildtype | positive | NaN | breast | exemestane | invasive ductal carcinoma |
GSM1029805 | ER+ | ER+ | ER+ | 46 | 51 | 0 | 1 | 0 | positive | female | 2 | NaN | breast | post | NaN | positive | NaN | breast | exemestane | invasive ductal carcinoma |
GSM1029806 | HER2+ | ER+ | ER+/HER2+ | 73 | 73 | 1 | 1 | 0 | positive | female | 3 | positive | breast | post | wildtype | positive | 18 | breast | anastrozole | invasive ductal carcinoma |
GSM1029807 | ER+ | ER+ | ER+ | 78 | 78 | 1 | 1 | 0 | positive | female | 2 | negative | breast | post | wildtype | negative | 5 | breast | anastrozole | invasive ductal carcinoma |
GSM1029808 | ER+ | ER+ | ER+ | 69 | 69 | 1 | 1 | 0 | positive | female | 3 | negative | breast | post | wildtype | positive | 2 | breast | exemestane | invasive ductal carcinoma |
GSM1029809 | HER2+ | HER2+ | ER-/HER2+ | 51 | 52 | 1 | 1 | 15 | negative | female | 2 | positive | breast | post | wildtype | negative | 11 | breast | letrozole | invasive ductal carcinoma |
GSM1029810 | TNBC | TNBC | TNBC | 48 | 50 | 1 | 1 | 17 | negative | female | 3 | negative | breast | post | wildtype | negative | 6 | breast | anastrozole | invasive ductal carcinoma |